Chargement en cours...
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
BACKGROUND: Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory...
Enregistré dans:
| Publié dans: | J Immunother Cancer |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5240303/ https://ncbi.nlm.nih.gov/pubmed/28105370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0205-2 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|